Low Dose Oxybutynin in Childhood Nocturnal Enuresis

To evaluate response to low dose oxybutynin in children with nocturnal enuresis. Forty one neurologically normal enuretic children who referred nephrology clinic in a 3- year period (2007-2009) received low dose oxybutynin (2.5-10 mg/day depending on the age) to define response to the drug in one and 3- month periods. No response, partially and full responses were defined as decreased in bed wetting in the rate of 0-49%,50-89% and ≥90% respectively. In first month of treatment, full, partial and no responses were reported in 3 (7.3%), 14(34.1%) and 24(58.6%) patients respectively. In non-responder patients 6 (25%) and 5(20.8 %) patients had full and partial responses in 3-month period, whereas 13 (54.2%) had no response. Side effects of the drug were reported in 5(12.2%) patients. Children with non-mono symptomatic nocturnal enuresis presented a better response to the drug than those with mono symptomatic nocturnal enuresis (75% versus 25%). There was no significant differences between age, gender, family history of enuresis and presence of absence of daytime urinary or bowel symptoms in responder and non-responder groups(P>0.05 for all). In this clinical report study, there was 68.3% treatment benefit and 12 % risk (side effects of the drug) with low dose oxybutynin, so it may have a role in treating nocturnal enuresis especially patients with NMNE who experience adverse effects of the drug with standard treatment.